JAK inhibitor
Showing 26 - 50 of 7,638
Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound Trial in Nagasaki (upadacitinib 15mg/day)
Recruiting
- Rheumatoid Arthritis
- +3 more
- upadacitinib 15mg/day
-
Nagasaki, JapanNagasaki University Hospital
Nov 24, 2021
Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)
Recruiting
- Chronic Hand Dermatitis
-
Rochester, New YorkUR Medicine Dermatology College Town
Aug 9, 2022
Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)
Recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- Steroid Refractory Graft Versus Host Disease
- Cellular Therapy
- Ruxolitinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, MDS Trial in Saint Louis (procedure, drug, other)
Recruiting
- Acute Myelogenous Leukemia
- +4 more
- Stem cell transplantation
- +3 more
-
Saint Louis, MissouriWashington University School of Medicine
Aug 23, 2022
Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis Trial in Caba, Ciudad Autonoma Buenos Aires (DMARDs, biologic
Recruiting
- Arthritis, Rheumatoid
- +2 more
- DMARDs
- +2 more
-
Caba, Buenos Aires, Argentina
- +1 more
Mar 26, 2021
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +2 more
-
Columbus, Ohio
- +2 more
Aug 10, 2022
Cicatricial Alopecia Trial in New York (PF-06651600)
Not yet recruiting
- Cicatricial Alopecia
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Sep 19, 2022
Advanced Hepatocellular Carcinoma Trial in London (Itacitinib (INCB039110))
Recruiting
- Advanced Hepatocellular Carcinoma
- Itacitinib (INCB039110)
-
London, United KingdomImperial College Healthcare NHS Trust
Jul 14, 2022
Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)
Not yet recruiting
- Vitiligo
- Effect of Drug
- JAK-2 inhibitor
- Topical corticosteroid
- (no location specified)
Mar 19, 2022
Bronchiolitis Obliterans Trial in Houston (Itacitinib, Itacitinib Adipate)
Recruiting
- Bronchiolitis Obliterans
- Itacitinib
- Itacitinib Adipate
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)
Completed
- Myelofibrosis
- Imetelstat 4.7 mg/kg
- Imetelstat 9.4 mg/kg
-
Birmingham, Alabama
- +71 more
Aug 17, 2021
Arteritis, Giant Cell Trial in Rochester (Baricitinib)
Completed
- Arteritis, Giant Cell
-
Rochester, MinnesotaMayo Clinic
Apr 7, 2022
Vitiligo, JAK Inhibitor Trial in Canada, United States (Ruxolitinib 1.5% cream, NB-UVB phototherapy)
Recruiting
- Vitiligo
- JAK Inhibitor
- Ruxolitinib 1.5% cream
- NB-UVB phototherapy
-
Fountain Valley, California
- +13 more
Jul 6, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Seattle (procedure, drug, radiation)
Recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jun 21, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia Trial in Houston (Ruxolitinib,
Completed
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Untreated Chronic Lymphocytic Leukemia
- Ruxolitinib
- Ruxolitinib Phosphate
-
Houston, TexasM D Anderson Cancer Center
Mar 23, 2021
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma Trial in Seattle
Recruiting
- Metastatic Leiomyosarcoma
- +17 more
- Itacitinib
- Laboratory Biomarker Analysis
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 13, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Duarte (procedure, drug, other)
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Allogeneic Hematopoietic Stem Cell Transplantation
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 2, 2021
Lupus or SLE, Nephritis Trial in Assiut (Baricitinib 4 MG, Baricitinib 2 MG, MMF)
Recruiting
- Lupus or SLE
- Nephritis
- Baricitinib 4 MG
- +2 more
-
Assiut, Yes, EgyptManal Hassanien
Jan 13, 2023
Recurrent Classical Hodgkin Lymphoma Trial in Cologne (Ruxolitinib)
Completed
- Recurrent Classical Hodgkin Lymphoma
-
Cologne, Germany1st Dept. of Medicine, Cologne University Hospital
Apr 3, 2020
Hemophagocytic Lymphohistiocytoses, Cytokine Storm Trial in Hangzhou (Dexamethasone, Etoposide, Ruxolitinib)
Not yet recruiting
- Hemophagocytic Lymphohistiocytoses
- Cytokine Storm
- Dexamethasone
- +2 more
-
Hangzhou, Zhejiang, ChinaThe Children's Hospital of Zhejiang University School of Medicin
Aug 4, 2022
Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis Trial in France (no intervention)
Recruiting
- Rheumatoid Arthritis
- +3 more
- no intervention
-
Antibes, France
- +59 more
Oct 25, 2022